Understand the source comparison
Peptides for High Blood Pressure: Protocol Comparison
Fermented dairy (IPP/VPP) Isoleucine-proline-proline, valine-proline-proline 3–5g peptides in 150–200ml product Competitive ACE inhibition (IC50 5–9 μM) 4–7 mmHg systolic after 8–12 weeks Most clinically validated approach. Consistent trial results, GRAS statu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Fermented dairy (IPP/VPP)
- Isoleucine-proline-proline, valine-proline-proline
- 3–5g peptides in 150–200ml product
- Competitive ACE inhibition (IC50 5–9 μM)
- 4–7 mmHg systolic after 8–12 weeks
- Most clinically validated approach. Consistent trial results, GRAS status, minimal adverse events
- Marine-derived (sardine, bonito)
- LKPNM, IKP sequences
- 1.5–3g peptide hydrolysate
- ACE inhibition + eNOS upregulation
- 5–9 mmHg systolic after 6–10 weeks
- Stronger acute effect than dairy peptides but less long-term data; fishy taste limits adherence
- Soy protein hydrolysate
- Multiple sequences (varies by preparation)
- 25–40g whole soy protein
- Mixed ACE inhibition and isoflavone-mediated vasodilation
- 2–5 mmHg systolic after 12+ weeks
- Weakest isolated peptide effect but beneficial as part of plant-based dietary pattern
- Synthetic ACE-inhibiting tripeptides
- Custom sequences (research use)
- 0.5–1g pure compound
- Direct ACE binding (higher affinity than food peptides)
- Variable. Research stage only
- Not approved for human consumption; available through research suppliers like Real Peptides for laboratory investigation